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Thromboembolic and neurologic 
sequelae of discontinuation of an 
antihyperlipidemic drug during 
ongoing warfarin therapy
Charles E. Leonard  1,2,3, Colleen M. Brensinger1,2, Warren B. Bilker1,2,4, Stephen E. 
Kimmel1,2,3,5, Heather J. Whitaker6 & Sean Hennessy1,2,3,7
Warfarin and antihyperlipidemics are commonly co-prescribed. Some antihyperlipidemics may 
inhibit warfarin deactivation via the hepatic cytochrome P450 system. Therefore, antihyperlipidemic 
discontinuation has been hypothesized to result in underanticoagulation, as warfarin metabolism is 
no longer inhibited. We quantified the risk of venous thromboembolism (VTE) and ischemic stroke 
(IS) due to statin and fibrate discontinuation in warfarin users, in which warfarin was initially dose-
titrated during ongoing antihyperlipidemic therapy. Using 1999–2011 United States Medicaid 
claims among 69 million beneficiaries, we conducted a set of bidirectional self-controlled case series 
studies—one for each antihyperlipidemic. Outcomes were hospital admissions for VTE/IS. The risk 
segment was a maximum of 90 days immediately following antihyperlipidemic discontinuation, 
the exposure of interest. Time-varying confounders were included in conditional Poisson models. 
We identified 629 study eligible-persons with at least one outcome. Adjusted incidence rate ratios 
(IRRs) for all antihyperlipidemics studied were consistent with the null, and ranged from 0.21 (0.02, 
2.82) for rosuvastatin to 2.16 (0.06, 75.0) for gemfibrozil. Despite using an underlying dataset of 
millions of persons, we had little precision in estimating IRRs for VTE/IS among warfarin-treated 
persons discontinuing individual antihyperlipidemics. Further research should investigate whether 
discontinuation of gemfibrozil in warfarin users results in serious underanticoagulation.
Drug-drug interactions are a serious public health problem. This problem is magnified in older adults, of whom 
>76% take two or more drugs1 and >50% take five or more drugs per month2. Given this degree of polypharmacy, 
it is not surprising that known drug-drug interactions are responsible for 13% of all adverse drug events3 and 
4.8% of hospital admissions4 in older adults. Few studies have examined clinically-important population-based 
health effects of interactions between an object (the affected drug) and precipitant (the affecting drug)5. Even 
fewer (and possibly no) studies have examined clinical sequelae of an offset drug-drug interaction—triggered by 
discontinuation of a precipitant drug in the presence of ongoing object drug therapy (Appendix Figure 1)6. The 
paucity of data on the health effects of drug interactions leaves critical knowledge gaps for prescribers, pharma-
cists, nurses, patients, editors and users of drug interaction compendia, and persons who design, manage, and use 
clinical decision support systems.
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Anticoagulants are consistently identified as among the most common causes of serious adverse drug events7. 
Underscoring this, the United States Department of Health and Human Services National Action Plan for Adverse 
Drug Event Prevention called for real world data on anticoagulant drug interactions7. Such interactions are of 
major concern since warfarin continues to be very commonly used (despite the rapid market uptake of direct 
oral anticoagulants)8,9, has a narrow therapeutic index6, may interact with almost every therapeutic class10, and 
is the leading cause of adverse drug event-related hospitalizations in older adults (the most common users of 
the drug9)11. Publically-available data from the United States Centers for Disease Control and Prevention12 
indicate that nearly 50% of older adult warfarin users also take an antihyperlipidemic drug. Yet, intermittent 
use (e.g., suboptimal adherence) and long-term discontinuation (e.g., intolerance to adverse effects, perceived 
lack of efficacy, harms outweigh benefits) of antihyperlipidemic therapy is common13,14. For example, approxi-
mately 25–50% of statin users will discontinue their lipid-lowering drug within 6–12 months after initiation15–17. 
Antihyperlipidemic drug discontinuation may trigger an offset drug-drug interaction and thereby place persons 
at risk for sequelae of underanticoagulation.
The primary hypothesized mechanism underlying this putative offset drug-drug interaction involves 
de-inhibition of warfarin’s hepatic metabolism. When warfarin is initiated during ongoing use of an antihyper-
lipidemic drug, warfarin may be dose-titrated in the presence of an antihyperlipidemic that inhibits warfarin’s 
inactivation18 by cytochrome P450 2C9, 3A, and/or 1A219,20. Therefore, less warfarin may be required to achieve a 
desired level of anticoagulation. Yet, upon discontinuing the antihyperlipidemic drug, metabolic inhibition is lost 
and the warfarin dose may be inadequate. Secondary mechanisms may include losses of the antihyperlipidemic’s 
plasma protein displacement of warfarin21–23 and pleotropic effects on platelets and the coagulation pathway24–26. 
As a result, such warfarin-treated patients may be underanticoagulated. To investigate this, we conducted a set 
of self-controlled case series studies to quantify and compare the rates of venous thromboembolism / ischemic 
stroke among concomitant users of warfarin upon discontinuation of individual antihyperlipidemic drugs.
Results
In our dataset of over 69 million beneficiaries, we identified 629 subjects who: a) concomitantly used warfarin 
and an antihyperlipidemic of interest; b) experienced at least one venous thromboembolism / ischemic stroke 
outcome during observation time; and c) met all other inclusion criteria. Subjects were predominantly female 
(65.0%) and non-Hispanic Caucasian (56.9%), with a median age of 69.1 years. Subjects contributed 93,764 
person-days of observation, 84,208 (89.8%) of which were in a non-hospital setting. The median and mean obser-
vation period length was 3.3 and 4.9 months, respectively. The risk, non-risk, and indeterminate risk segments 
accounted for 12.5%, 84.3%, and 3.2% of person-days, respectively. Subject characteristics stratified by antihyper-
lipidemic of interest are presented in Table 1. Note that there were ten or fewer persons constituting the cerivas-
tatin, fluvastatin, and pitavastatin cohorts; therefore, self-controlled case series conditional Poisson regression 
models were not run for these agents.
For the primary analysis, the crude incidence rate ratios for venous thromboembolism/ischemic stroke within 
90 days of antihyperlipidemic discontinuation ranged from 0.28 (0.03–2.80) for rosuvastatin to 0.83 (0.06–11.23) 
for gemfibrozil. Confounder-adjusted incidence rate ratios ranged from 0.21 (0.02–2.82) for rosuvastatin to 2.16 
(0.06–75.00) for gemfibrozil. Crude and adjusted incidence rate ratios for pravastatin, the prespecified referent, 
were 0.79 (0.34–1.83) and 1.36 (0.54–3.45), respectively. See Fig. 1 and Appendix Table 1. Findings from second-
ary analyses are presented in Table 2 and Appendix Table 2.
Discussion
We examined rates of venous thromboembolism/ischemic stroke among users of warfarin upon discontinua-
tion of concomitantly-prescribed antihyperlipidemic drugs. Using rigorous pharmacoepidemiologic methods 
and a dataset of healthcare claims from tens of millions of persons, we did not identify any statistically significant 
confounder-adjusted associations between antihyperlipidemic discontinuation and our composite outcome. Our 
findings’ limited precision prohibits us from drawing definitive conclusions; this is a notable limitation. However, 
it is worth noting that adjusted incidence rate ratios vs. pravastatin were less than one for fenofibrate and nearly 
always less than one for each statin under study. Results when combining antihyperlipidemics of interest by 
likelihood of cytochrome P450 2C9 inhibition using two different groupings resulted in substantial increases 
in precision and still failed to demonstrate a statistically significant association. Because the adjusted incidence 
rate ratio for gemfibrozil vs. pravastatin was 1.59, one could hypothesize that discontinuing gemfibrozil might 
increase one’s risk of venous thromboembolism/ischemic stroke. This finding aligns with our prior demonstration 
that warfarin plus gemfibrozil (vs. pravastatin) results in a 50% increased risk of gastrointestinal bleeding and 
intracranial hemorrhage27, a result of overanticoagulation. Therefore, if warfarin is dose-titrated in the presence 
of gemfibrozil exposure, a lower dose of warfarin may be required to reach the desired level of anticoagulation. If 
gemfibrozil therapy is subsequently discontinued, this may place the patient at risk for sequelae of underantico-
agulation from suboptimal warfarin dosing. This may emphasize the importance of calls to monitor the level of 
anticoagulation upon initiating and discontinuing drugs that may inhibit warfarin’s metabolism6,28,29, including 
certain antihyperlipidemics6.
To our knowledge, no prior population-based comparative safety study has investigated clinical outcomes 
associated with the discontinuation of individual statins and/or fibrates in users of a coumarin derivative. 
With respect to a surrogate endpoint, Zhelyazkova-Savova et al. examined changes in laboratory measures in a 
cross-sectional study elucidating potential statin drug interactions (Appendix Table 3)30. Among 69 Bulgarian 
inpatients concomitantly-exposed to acenocoumarol and a statin, one (1.4%) individual experienced a 22.6% 
reduction in their international normalized ratio (3.1 to 2.4) upon discontinuation of atorvastatin30. In a 
cross-sectional study examining a potential drug interaction between warfarin and amiodarone (a non-statin, 
non-fibrate precipitant drug that inhibits the metabolism of warfarin via cytochrome P450, similar to some statins 
www.nature.com/scientificreports/
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Antihyperlipidemic of interest
atorva ceriva* feno fluva* gem lova pitava* prava rosuva simva
Persons 219 ** 24 ** 11 36 ** 68 22 235
Persons-days of observation period, median (Q1-Q3) per individual
112.0 
(45.0–
197.0)
79.5 
(31.5–
128.0)
98.0 
(57.5–
217.0)
66.0 
(43.0–
110.0)
43.0 
(29.0–
126.0)
74.5 
(40.5–
189.0)
17.0 
(17.0–
17.0)
102.0 
(53.0–
203.5)
109.0 
(57.0–
171.0)
100.0 
(46.0–
190.0)
Person-days of observation period, total 34,789 319 3,772 1,156 811 4,726 17 10,610 2,585 34,979
% person-days of observation period in risk segment 13.5 23.2 13.2 23.8 28.0 12.5 0.0 12.6 11.7 10.6
Outcomes during observation period 238 ** 27 11 11 38 ** 73 23 248
VTE 170 ** ** ** ** 26 ** 52 ** 162
IS 68 0 ** ** ** 12 0 21 ** 86
Demographics Group % of persons (unless otherwise noted)
Age in years at start of observation period Median (Q1-Q3)
68.9 
(54.3–
78.1)
80.5 
(72.0–
86.5)
61.3 
(48.4–
69.9)
66.5 
(51.8–
84.0)
57.3 
(46.1–
63.4)
72.2 
(57.1–
80.2)
62.5 
(62.5–
62.5)
71.4 
(57.2–
78.7)
63.8 
(55.3–
74.4)
71.1 
(59.4–
80.0)
Sex Female 69.9 ** 66.7 ** ** 61.1 ** 58.8 77.3 62.6
Race
White 60.3 ** 79.2 ** ** 55.6 0.0 60.3 ** 51.9
Black 16.9 ** ** 0.0 ** ** ** ** ** 23.8
Hispanic/Latino 8.7 0.0 0.0 ** ** ** 0.0 ** ** 11.5
Other/Unknown 14.2 ** ** ** ** ** ** ** ** 12.8
State of residence
California 39.3 ** ** ** ** 41.7 0.0 54.4 ** 29.8
Florida 14.2 ** ** ** ** ** ** 17.6 ** 17.9
New York 24.2 0.0 ** ** ** ** 0.0 ** ** 26.0
Ohio 13.2 ** ** ** ** ** ** ** ** 12.3
Pennsylvania 9.1 0.0 ** ** ** ** 0.0 ** ** 14.0
Calendar year at start of observation period†
1999 ** ** ** ** 0.0 ** 0.0 ** 0.0 **
2000 ** ** 0.0 ** ** ** 0.0 ** 0.0 **
2001 10.0 ** ** ** ** ** 0.0 ** 0.0 5.5
2002 9.6 0.0 0.0 0.0 ** ** 0.0 ** 0.0 4.7
2003 7.3 0.0 ** ** 0.0 ** 0.0 ** 0.0 4.7
2004 8.2 0.0 0.0 ** ** ** 0.0 ** 0.0 **
2005 10.5 0.0 ** 0.0 ** ** 0.0 ** ** **
2006 12.3 0.0 ** 0.0 0.0 ** 0.0 ** ** 4.7
2007 9.1 0.0 ** ** 0.0 ** 0.0 ** 0.0 11.5
2008 10.5 0.0 ** 0.0 ** ** 0.0 ** ** 13.6
2009 8.7 0.0 ** 0.0 ** ** 0.0 ** ** 14.5
2010 5.5 0.0 ** 0.0 ** ** 0.0 ** ** 17.4
2011 ** 0.0 ** 0.0 0.0 ** ** ** ** 14.9
Medicare enrolled at start of observation 
period
Yes
79.0 ** 75.0 ** ** 88.9 ** 88.2 81.8 77.4
Nursing home resident at start of observation 
period 8.7 ** ** ** ** ** ** ** ** 17.4
Pre-defined time-varying covariates Group % of person-days (unless otherwise noted)
Major non-chronic risk factor for outcome
    VTE in prior 90 days
Yes
30.3 68.0 54.9 17.9 69.2 32.2 ** 30.9 38.4 28.9
    IS in prior 90 days 9.0 0.0 3.2 12.5 5.5 7.5 0.0 8.5 20.0 12.4
    Hospital discharge on current day or in 
prior 90 days 31.6 49.2 41.6 35.7 70.4 36.1 ** 30.2 41.5 34.2
Major non-chronic disease that may affect coagulation
    Acute infection on current day or in prior 
14 days Yes 15.3 16.9 10.5 15.6 14.1 10.5 ** 16.7 16.1 15.3
Drug that may affect coagulation†
    anticoagulant, oral non-warfarin
Yes
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    anticoagulant, injectable/subcutaneous 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.2 0.5
    antiplatelet, oral 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    aspirin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Drug that may interact with warfarin
    interacting drug, oral, per Truven‡
Yes
29.3 42.9 30.4 10.4 26.3 38.6 0.0 30.7 12.4 17.3
    CYP2C9 inhibitor‡ 11.0 42.6 15.6 0.0 7.5 10.3 0.0 8.4 2.3 5.0
    CYP2C9 inducer† 5.8 0.0 0.0 0.0 0.0 0.6 0.0 6.1 0.0 1.6
Continued
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and fibrates), McDonald et al. quantified that amiodarone discontinuation necessitated a 24.8% mean increase 
in warfarin dose to maintain the international normalized ratio of 27 outpatients between 2.0 and 3.0 (Appendix 
Table 3)31. It is possible that amiodarone discontinuation during warfarin use may be more clinically relevant than 
the warfarin-antihyperlipidemic offset drug-drug interaction examined herein, particularly with respect to statin 
discontinuation. This warrants further investigation.
Our study has notable strengths. It is the first population-based comparative safety study to examine clinical 
sequelae of an offset drug interaction among warfarin users. We utilized a self-controlled study design, prespec-
ified a reference exposure, and controlled for time-varying covariates to minimize confounding. We conducted 
numerous secondary analyses to further elucidate the association between exposure and outcome and to test the 
Antihyperlipidemic of interest
atorva ceriva* feno fluva* gem lova pitava* prava rosuva simva
Drug that may increase risk of VTE alone† Yes 26.7 0.0 31.0 11.5 55.7 40.3 0.0 19.5 19.1 21.9
Drug that may increase risk of IS alone‡ Yes 24.8 42.6 30.0 3.1 9.0 25.0 0.0 19.5 13.2 23.8
Drug that may increase risk of VTE and IS† Yes 15.9 46.1 17.7 12.8 24.7 26.2 0.0 19.1 18.8 10.2
Therapeutic drug monitoring for warfarin Yes 32.5 41.1 31.8 27.3 29.1 28.0 0.0 31.0 31.8 31.1
Average daily warfarin dose, in milligrams Median (Q1-Q3)
4.8 
(2.5–
5.0)
4.0 
(4.0–4.0)
3.0 
(2.0–
5.0)
4.0 
(2.5–
5.0)
5.0 
(3.7–
6.0)
5.0 
(2.5–
5.0)
7.5 
(7.5–7.5)
2.5 
(1.5–
5.0)
3.0 
(2.0–5.0)
4.0 
(2.0–
5.0)
Table 1. Characteristics of warfarin users under study, by antihyperlipidemic cohort. Atorva = atorvastatin; 
CYP = cytochrome P450; feno = fenofibrate; gem = gemfibrozil; IS = ischemic stroke; lova = lovastatin; 
prava = pravastatin; Q = quartile; rosuva = rosuvastatin; simva = simvastatin; VTE = venous thromboembolism. 
*Excluded from further study because few persons in cohort. **Value suppressed to ensure subject anonymity, 
consistent with Centers for Medicare and Medicaid Services privacy rule for small cells; cell < 11 or would 
permit back-calculation of a cell < 11. †If dispensed on current day or in prior 30 days. ‡If dispensed on current 
day or in prior 30 days for chronically-administered drugs (14 days for acutely-administered drugs).
Figure 1. Risk of venous thromboembolism/ischemic stroke within 90 days of discontinuing an 
antihyperlipidemic of interest in the presence of ongoing warfarin therapy. Panel A (top): Crude and adjusted 
incidence rate ratios. Panel B (bottom): Ratio of crude and adjusted incidence rate ratios for antihyperlipidemic 
of interest vs. pravastatin. Figure 1 presents primary findings of study. Black squares represent crude incidence 
rate ratios. White circles represent confounder-adjusted incidence rate ratios. Values for incidence rate ratios 
and 95% confidence intervals are presented in Appendix Table 1.
www.nature.com/scientificreports/
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robustness of findings to assumptions of the self-controlled design. Finally, components of our outcome defini-
tion had high positive predictive values and moderate-to-high sensitivities.
Our study also has limitations. First, despite using a dataset of over 69 million individuals, we had limited 
statistical power. Second, we lacked access to biosamples and therefore could not examine the impact of genetic 
cytochrome P450 polymorphisms. Third, we lacked data on adherence to dispensed warfarin and antihyperlipi-
demic prescriptions. Fourth, we lacked access to results of laboratory orders (e.g. international normalized ratio 
values); such findings are not included in Centers for Medicare and Medicaid Services data. Fifth, administrative 
databases may poorly capture some lifestyle behaviors and nonprescription therapies that affect venous throm-
boembolism and/or ischemic stroke risk; yet, such factors seem unlikely to differ substantially by antihyperlipi-
demic exposure group. Finally, our results may not be generalizable beyond a United States Medicaid population. 
Nevertheless, this population was specifically chosen because of its inherent vulnerability and inclusion of large 
numbers of women and minorities—groups typically understudied. Biologic associations identified in Medicaid 
populations are often replicated in commercially insured populations and vice versa32.
Drug interactions with warfarin are a major public health concern. Nearly all existing population-based 
studies of warfarin interactions and clinical outcomes have examined risk periods defined by commencement of 
concomitant use of warfarin and a precipitant drug. In contrast, we examined putative offset drug-drug interac-
tions—defined by discontinuation of the precipitant drug—hypothesizing that de-inhibition of warfarin’s hepatic 
metabolism would lead to serious sequelae of underanticoagulation. We did not identify a clear relationship 
between discontinuing antihyperlipidemics and clinical events. The potential safety signal that concomitant users 
of warfarin and gemfibrozil may be at increased risk for venous thromboembolism/ischemic stroke upon discon-
tinuation of gemfibrozil requires further study. The mechanism underlying this possible offset interaction also 
needs further elucidation, but is unlikely to solely involve a pharmacokinetic interaction mediated by cytochrome 
P450 inhibition or displacement of binding from plasma proteins.
Analysis*
Ratio of adjusted IRRs (95% CIs) for antihyperlipidemic of interest vs. referent
fibrates statins
feno gem rosuva atorva prava lova simva
Further elucidating the association between antihyperlipidemic discontinuation and outcome
Stratify risk 
segment
Days 1–30 0.25 (0.03–1.76) 5.11 (0.10–265.8) 0.21 (0.02–2.64) 0.44 (0.15–1.30) referent 0.29 (0.06–1.47) 0.42 (0.14–1.32)
Days 31–60 ND ND ND ND referent ND ND
Days 61–90 ND ND ND 0.41 (0.03–5.63) referent ND 0.21 (0.01–5.33)
Deconstruct 
composite 
outcome
VTE 0.15 (0.01–1.77) 1.45 (0.05–41.1) 0.35 (0.02–7.56) 0.43 (0.12–1.54) referent 0.63 (0.11–3.73) 0.65 (0.18–2.40)
IS 0.45 (0.02–13.1) ND ND 0.88 (0.11–6.70) referent ND 0.47 (0.06–3.55)
Lump antihyperlipidemics of interest by 
likelihood of CYP2C9 inhibition** 0.71 (0.37–1.35) referent
Lump antihyperlipidemics of interest by 
likelihood of interacting with warfarin, 
per Truven Micromedex and Facts & 
Comparisons DDI module ratings**
0.86 (0.45–1.64) referent †
Assessing SCCS underlying assumptions, minimizing the role of bias and/or confounding
Increase maximum length of risk 
segment from 90 to 120 days†† 0.19 (0.03–1.32) 1.09 (0.02–65.0) 0.21 (0.02–2.04) 0.46 (0.16–1.29) referent 0.39 (0.08–1.81) 0.53 (0.18–1.56)
Exclude segments occurring before the 
first risk segment (i.e., conduct left-
censored unidirectional SCCS)
ND ND ND 0.71 (0.06–8.36) referent ND 0.36 (0.03–4.20)
Exclude segments occurring after 
the first risk and indeterminate risk 
segments (i.e., conduct right-censored 
unidirectional SCCS)
0.27 (0.03–2.49) 2.54 (0.06–104.6) 0.51 (0.03–7.94) 0.82 (0.26–2.59) referent 0.85 (0.12–5.78) 1.01 (0.31–3.27)
Reclassify second or later risk and 
indeterminate risk segments as non-risk 
segments
0.22 (0.03–1.59) 1.51 (0.04–59.3) 0.29 (0.02–4.41) 0.54 (0.18–1.58) referent 0.43 (0.08–2.14) 0.66 (0.22–1.98)
Include average daily dose of warfarin as 
covariate in outcome model 0.24 (0.03–2.09) 8.55 (0.28–259.0) 0.35 (0.02–5.79) 0.90 (0.27–3.03) referent 0.37 (0.06–2.29) 0.97 (0.28–3.32)
Exclude subjects with >1 outcome 
during the observation period 0.37 (0.05–2.77) 2.42 (0.06–98.7) 0.34 (0.02–5.27) 0.86 (0.26–2.89) referent 0.74 (0.12–4.42) 1.19 (0.35–4.02)
Exclude subjects that die during the 
observation period 0.21 (0.03–1.52) 1.19 (0.04–36.7) 0.15 (0.01–2.30) 0.43 (0.14–1.27) referent 0.34 (0.06–1.86) 0.62 (0.20–1.90)
Table 2. Findings from prespecified and post hoc secondary analyses. Atorva = atorvastatin; CI = confidence 
interval; CYP = cytochrome P450; DDI = drug-drug interaction; feno = fenofibrate; gem = gemfibrozil; 
IRR = incidence rate ratio; IS = ischemic stroke; lova = lovastatin; ND = not detectable/model produced 
unstable estimates; prava = pravastatin; rosuva = rosuvastatin; SCCS = self-controlled case series; 
simva = simvastatin; VTE = venous thromboembolism. *Examining VTE/IS as composite outcome, unless 
otherwise noted. **Post hoc analysis. †IRR for combined fenofibrate/gemfibrozil/rosuvastatin/lovastatin/
simvastatin vs. atorvastatin/pravastatin listed in merged fenofibrate-gemfibrozil-rosuvastatin cell. ††Thereby 
increases maximum length of indeterminate risk period from 90 to 120 days.
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Methods
Overview and study population. We conducted bidirectional self-controlled case series studies of adult 
users of warfarin experiencing the composite outcome of venous thromboembolism/ischemic stroke. Although 
the phrase “case series” within self-controlled case series may seem to imply the absence of a comparator, the 
design is actually a rigorous, reproducible, controlled epidemiologic method33; it is the cohort analogue of the bet-
ter known case-crossover design34. In a self-controlled case series study, individuals serve as their own referent, 
therefore eliminating confounding by time-invariant factors35. This is a major advantage over traditional cohort 
and case-control approaches, yet is accompanied by the following key assumptions: the occurrence of an outcome 
should not appreciably affect subsequent exposures; outcome rates are constant within intervals; and outcomes 
must be independently recurrent or rare35.
The study’s underlying cohorts, one for each of ten antihyperlipidemics of interest, consisted of episodes 
of new warfarin use initiated during ongoing therapy for that antihyperlipidemic. Study data included demo-
graphic, enrollment, and healthcare claims from the United States Medicaid programs of California, Florida, 
New York, Ohio, and Pennsylvania from 1999–201132. These states comprise ~38% of the national enrollment36, 
with the 13-year dataset recording the experience of more than 69 million cumulative enrollees and nearly 222 
million person-years of observation. Because a substantive proportion of Medicaid beneficiaries are co-enrolled 
in Medicare37–39, we included Medicare claims to ascertain a more complete picture of their healthcare40,41. We 
linked these datasets to the Social Security Administration Death Master File to supplement death dates included 
in Medicaid and Medicare enrollment files.
Study cohorts. Separate cohorts were constructed for each antihyperlipidemic of interest, serving as bases 
for each self-controlled case series study. For persons 18–100 years of age, we utilized National Drug Codes and 
days’ supply values on prescription claims to build episodes of warfarin exposure. We allowed a 7-day grace 
period between contiguous warfarin prescriptions (and at the end of the terminal warfarin prescription) to 
account for imperfect adherence. This approach was repeated for each antihyperlipidemic of interest, thereby 
allowing us to identify persons concomitantly exposed to warfarin and an antihyperlipidemic. We then identi-
fied each person’s first concomitant use episode during which the antihyperlipidemic drug was initiated at least 
30 days prior to warfarin; this ensured that warfarin was initially dose titrated while hepatic cytochrome P450 
isozymes were already inhibited by the antihyperlipidemic (if applicable). Further, as the self-controlled case 
series design is a “case-only” approach, each person under study was required to experience an outcome during 
their observation period (defined below). If fewer than 10 persons constituted a given cohort, the antihyperlipi-
demic was excluded from further study.
Observation and pre-observation baseline periods. For each cohort member meeting inclusion cri-
teria, their observation period included all person-days of the warfarin episode that defined concomitancy. The 
observation period began upon warfarin initiation and was censored upon the earliest of: a) the end of the war-
farin episode initially defining concomitancy (defined by exhausting days’ supply [plus terminal grace period] 
or switching to a different oral anticoagulant); b) a dispensing for an antihyperlipidemic other than that initially 
defining concomitancy; c) a >7-day gap in Medicaid enrollment; d) the end of the study dataset; and e) death. 
Note that occurrence of an outcome did not censor observation time. This helped uphold the key self-controlled 
case series assumption of no event-dependent censoring42 and thereby avoided introducing bias of an unpredict-
able direction43.
A baseline period was defined as the 180 days immediately before the observation period. It was required to 
be devoid of: a) a >7-day gap in Medicaid enrollment; b) a procedure code indicative of hepatic cytochrome P450 
2C9 or vitamin K epoxide reductase complex genotyping—suggestive that the prescriber used genetics to guide 
warfarin dose titration; and c) a prescription claim for warfarin or any other oral anticoagulant—otherwise, a 
prescriber may not dose-titrate but rather reinstitute an old, tolerated dose of warfarin.
Categorizing observation period follow-up time. Person-days within each observation period were 
assigned to mutually-exclusive risk, non-risk, and indeterminate risk segments—with risk segments commen-
surate with a biologically plausible time frame during which antihyperlipidemic discontinuation in the presence 
of warfarin may be expected to increase risk of the outcome44,45. The risk segment consisted of a maximum 
of 90 person-days immediately following the end of the antihyperlipidemic episode initially defining concom-
itancy. The indeterminate risk segment consisted of a maximum of 90 person-days immediately following the 
risk segment. These segments could be <90 days in length if censored (described above) or if the antihyperlipi-
demic initially defining concomitancy was re-initiated. The non-risk segment consisted of all other person-days 
of observation time not assigned to a risk or indeterminate risk segment. Therefore, non-risk segments could 
occur both before and after the risk segment, consistent with a bidirectional self-controlled case series design; this 
standard approach helped to minimize exposure trend bias46. Of note, each observation period was not required 
to have person-days in all segments, yet only observations with both risk and non-risk segments contributed to 
the estimation of the incidence rate ratio for the association of interest. See Fig. 2 for a graphical representation of 
concomitant use episodes potentially eligible for inclusion.
Exposure of interest and covariates. The exposure of interest was the antihyperlipidemic drug initially 
defining concomitancy that was subsequently discontinued in the presence of warfarin. Agents included atorvas-
tatin, cerivastatin, fenofibrate, fluvastatin, gemfibrozil, lovastatin, pitavastatin, pravastatin, rosuvastatin, and sim-
vastatin. As dictated by the methodologic approach, each of the exposures of interest was examined in a separate 
self-controlled case series study. Pravastatin served as a prespecified control precipitant5 referent because it is a 
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negligible inhibitor of hepatic cytochrome P450 isozymes47 involved in the metabolism of warfarin18 and thus not 
expected to interact pharmacokinetically. Consequently, the discontinuation of pravastatin during ongoing warfa-
rin therapy (dose-titrated while pravastatin was on board) would not be expected to lead to underanticoagulation.
The self-controlled case series design implicitly controls for time-invariant covariates48. We therefore consid-
ered only time-varying covariates as potential confounders. We included, in each regression model, covariates 
from the following broad categories: a) major non-chronic risk factors for venous thromboembolism or ischemic 
stroke; b) drugs that may increase the risk of venous thromboembolism, ischemic stroke, or both49; c) major 
non-chronic diseases that may affect coagulation; d) drugs that may affect coagulation; e) drugs that may interact 
with warfarin50,51; and f) therapeutic drug monitoring for warfarin (i.e., an order for an international normal-
ized ratio). We added a time-varying covariate for average daily warfarin dose in a secondary analysis; this was 
relegated to a secondary analysis since warfarin dose is difficult to ascertain from prescription dispensings. See 
Appendix Table 4 for additional detail.
Outcome of interest. The composite outcome was hospitalization for venous thromboembolism or 
ischemic stroke—serious sequelae of underanticoagulation—identified by International Classification of Diseases 
9th Revision Clinical Modification discharge diagnosis codes on inpatient claims. Operational definitions52–56, 
including quantitative measures of algorithm performance, are presented in Table 3.
Analytic approach and statistical analysis. For each self-controlled case series study, we constructed an 
analytic file in which the unit of observation was the person-day of observation time. The dependent variable was 
an indicator for outcome. Independent variables included a unique subject identifier, the subject’s observation 
period, the segment within the observation period, and other time-varying covariates discussed above. The pri-
mary analysis examined outcome incidence during the entire risk segment(s) vs. incidence during the non-risk 
segment(s). We used conditional Poisson regression models to estimate incidence rate ratios and 95% confidence 
Figure 2. Examples of concomitant use episodes of warfarin and lovastatin eligible for inclusion. Panel A (top 
two): Persons with risk, indeterminate risk, and non-risk segments. Panel B (bottom): Person with non-risk 
segment only. Figure 2 presents potential methods of cohort entry, using concomitant use of warfarin and 
lovastatin as an example. Lightning bolts represent hypothetical outcomes.
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intervals33,48. We conducted numerous secondary analyses (Appendix Table 5) to examine the robustness of our 
findings and assess potential violations of the design’s underlying assumptions as a measure of good practice35. 
We calculated ratios of incidence rate ratios in which the effect estimate for each antihyperlipidemic of interest 
was in the numerator and the effect estimate for pravastatin (as the prespecified referent) was in the denominator.
Analyses were conducted using SAS (SAS Institute Inc.: Cary, NC). The research described herein was 
approved via expedited mechanism by the institutional review board of the University of Pennsylvania. As the 
research was determined to be no greater than minimal risk, the board issued a waiver of informed consent. 
Methods related to human subjects research were developed and carried out in accordance with relevant guide-
lines and regulations.
Data availability. Data that support study findings are available from the Centers for Medicare and Medicaid 
Services. Restrictions apply to the availability of these data, which were used by this study under a permissive data 
use agreement, and so are not publicly available. However, data may be available from the authors upon reasona-
ble request and with permission from the Centers for Medicare and Medicaid Services.
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